Roche

Roche will take responsibility for subsequent development activities, including preclinical research, and oversee the programmes as they progress towards potential commercialisation.

Astex will also qualify for development, regulatory, and commercial milestone payments exceeding US$465 million, totaling US$490 million with the upfront payment included.

Unlike conventional sequencing technologies, Axelios 1 uses SBX chemistry to convert DNA or RNA molecules into enlarged surrogate polymers known as Xpandomers.

The Bundibugyo strain remains particularly challenging because no approved vaccine or specific treatment is currently available.

Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.

Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.

The European Medicines Agency rejected Elevidys for ambulatory patients last year, citing insufficient evidence of effectiveness.

C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development